Surgery · 2025
Reassessing false-negative rate and size cutoff for papillary thyroid cancer with fine-needle aspiration in thyroid nodules.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vaghaiwalla Tanaz M, Henriksen Elliott M, Chang Jonathan, Saghira Cima, Lew John I
Аннотация
BACKGROUND: Fine-needle aspiration is the primary diagnostic tool for malignancy in thyroid nodules. However, fine-needle aspiration of larger nodules may yield greater false-negative rates for thyroid cancer. This study evaluates the performance of fine-needle aspiration in the diagnosis of papillary thyroid cancer across various thyroid nodule sizes.
METHODS: A retrospective study was conducted using prospectively collected data from 2,525 patients who underwent initial fine-needle aspiration and thyroidectomy between 2008 and 2022 at a single tertiary institution. Patients aged ≥18 years with Bethesda category II or VI thyroid nodules by fine-needle aspiration and a final histopathologic diagnosis of papillary thyroid cancer were included. Thyroid nodules were stratified by size: <1 cm, 1.0-1.99 cm, 2.0-2.99 cm, 3.0-3.99 cm, and ≥4.0 cm. Final histopathology was correlated with preoperative fine-needle aspiration Bethesda II and VI results. Statistical analysis was performed using analysis of variance and post-hoc testing.
RESULTS: A total of 753 patients were included in the analysis: 634 women (84.2%) and 119 men (15.8%), with a mean age of 49 years. Sensitivity, specificity, positive predictive value, negative predictive value, false positive, and false negative rates for fine-needle aspiration were 84.8%, 96.5%, 96.8%, 83.9%, 3.4%, and 15.2%, respectively. False-negative rates increased with thyroid nodule size: 3.4% (n = 2) for nodules <1 cm, 4.9% (n = 8) for 1.0-1.99 cm, 16.2% (n = 18) for 2.0-2.99 cm, 46.4% (n = 26) for 3.0-3.99 cm, and 46.2% (n = 12) for nodules ≥4.0 cm. Significant differences in false-negative rates were observed for nodules ≥3.0 cm (P < .001). Post-hoc testing revealed a significant difference between the ≥3 cm and <3 cm groups. No significant difference was found between nodules of 3.0-3.99 cm and ≥4.0 cm.
CONCLUSION: Although a thyroid nodule size >4 cm is traditionally considered an indication for thyroidectomy, this study demonstrates an increased incidence of false-negative results for PTC with thyroid nodules ≥3 cm. Future studies are needed to validate these findings.
METHODS: A retrospective study was conducted using prospectively collected data from 2,525 patients who underwent initial fine-needle aspiration and thyroidectomy between 2008 and 2022 at a single tertiary institution. Patients aged ≥18 years with Bethesda category II or VI thyroid nodules by fine-needle aspiration and a final histopathologic diagnosis of papillary thyroid cancer were included. Thyroid nodules were stratified by size: <1 cm, 1.0-1.99 cm, 2.0-2.99 cm, 3.0-3.99 cm, and ≥4.0 cm. Final histopathology was correlated with preoperative fine-needle aspiration Bethesda II and VI results. Statistical analysis was performed using analysis of variance and post-hoc testing.
RESULTS: A total of 753 patients were included in the analysis: 634 women (84.2%) and 119 men (15.8%), with a mean age of 49 years. Sensitivity, specificity, positive predictive value, negative predictive value, false positive, and false negative rates for fine-needle aspiration were 84.8%, 96.5%, 96.8%, 83.9%, 3.4%, and 15.2%, respectively. False-negative rates increased with thyroid nodule size: 3.4% (n = 2) for nodules <1 cm, 4.9% (n = 8) for 1.0-1.99 cm, 16.2% (n = 18) for 2.0-2.99 cm, 46.4% (n = 26) for 3.0-3.99 cm, and 46.2% (n = 12) for nodules ≥4.0 cm. Significant differences in false-negative rates were observed for nodules ≥3.0 cm (P < .001). Post-hoc testing revealed a significant difference between the ≥3 cm and <3 cm groups. No significant difference was found between nodules of 3.0-3.99 cm and ≥4.0 cm.
CONCLUSION: Although a thyroid nodule size >4 cm is traditionally considered an indication for thyroidectomy, this study demonstrates an increased incidence of false-negative results for PTC with thyroid nodules ≥3 cm. Future studies are needed to validate these findings.